Keytruda (pembrolizumab) given accelerated approval for cervical cancer

Last updated: 01 November 2019

You can legally access new medicines, even if they are not approved in your country.

Learn how

Cervical cancer patients with disease progression on/after chemotherapy have a new treatment available in the form of Keytruda (pembrolizumab). 

The FDA has given accelerated approval to Keytruda (pembrolizumab), following a new phase II KEYNOTE-158 trial.

According to oncological specialists, treatments have been lacking in the past for previously treated patients in this area. This approval, therefore, provides a much-needed option.

Read more about the accelerated approval in this OncLive article.